[Ip-health] MSF responds to latest Access to Medicines Index rankings

Joanna Keenan joanna.l.keenan at gmail.com
Mon Nov 14 09:52:46 PST 2016

MSF responds to today's release of the latest Access to Medicines Index

MSF responds to latest Access to Medicines Index rankings

“MSF appreciates the efforts of the Access to Medicines Index to collect
data that sheds light on the policies and practices of the pharmaceutical
industry - an industry which remains deeply shrouded in, and benefits from,
secrecy.  While it is important to document strategies that companies have
taken forward to address unmet health needs, our experience is that the few
measures that companies often highlight are dramatically outweighed by many
hidden practices that undermine access to medicines.  GSK, the leader in
the Access to Medicines Index, and Pfizer both recently reduced the price
of their pneumococcal conjugate vaccine for humanitarian organisations
working in emergencies, but both companies continue to charge unaffordable
prices in middle-income countries.

Although ranked in the top 10 companies of the Access to Medicines Index,
Gilead has priced its hepatitis C medicines largely out of reach for the
majority of people with hepatitis C, who live in middle-income countries
that are not included in Gilead’s licensing agreements with generic
producers.  Additionally, as pointed out in the Access to Medicines Index
report, registration for existing hepatitis c drugs such as sofosbuvir and
sofosbuvir/ledipasvir have not been filed or made available in the majority
of countries in need.

“Currently the extent to which people around the world are being left
behind by companies in the Access to Medicine Index undermines the
rationale for ranking companies as any better or worse than each other.  The
industry as a whole is failing people and health care workers around the
world, and increasingly their practices are also causing serious challenges
in rich countries.  Most of the companies in the Access to Medicine Index,
and many others, spend significant resources influencing governments to
refrain from taking measures that protect the health and well-being of
their people, and then seek to replace government action with voluntary
industry measures.   Even as companies can and should strive to do more,
the only way to really deliver lasting change for the people we serve, and
many others, will be for governments to set clear access requirements that
all companies must meet.”

-          Rohit Malpani, Director, Policy and Analysis, Médecins Sans
Frontières Access Campaign

*Joanna Keenan*

Press Officer

Médecins Sans Frontières - Access Campaign

P: +41 22 849 87 45

M: +41 79 203 13 02

E: joanna.keenan[at]geneva.msf.org

T: @joanna_keenan




More information about the Ip-health mailing list